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tem. The transfusion of blood during surgery was associated with increased risk of
wound infection (OR 1.92–3.82, p0.02), post-operative complications (OR 2.63,
p0.001) and increasedmortality (OR 1.6–10.2, p0.05). Peri-operative blood trans-
fusionwas also associatedwith an increasedhospital stay of 4.1 days inHongKong,
equating to approximately US$4300 in excess hospital expenses. CONCLUSIONS:
This review has identified several areas in which peri-operative bleeding may in-
crease the burden to the Hong Kong health care system. This includes the greater
need for transfusions, risk of complications and extended hospital stay. Accord-
ingly, improvements in haemostasis have the potential to reduce direct health care
resource utilisation through a reduction in blood use, hospital length of stay, need
for additional procedures and patient mortality.
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OBJECTIVES: Fibromyalgia is a neuropathic syndrome which is more common in
adult females. Pregabalin is the first medicine which was approved by FDA for
treatment of fibromyalgia. In this study we aim to evaluate the cost- effectiveness
of pregabalin in the treatment of fibromyalgia in Iran.METHODS: To evaluate the
efficacy of pregabalin, a systematic review by searching on PubMed, Scopus and
Google scholar was conducted. The keywords included “fibromyalgia” and “prega-
balin”. The outcome of interest in the reports was the score pain. To evaluate costs
of treatment, the direct costs were considered. RESULTS: Out of 8994 primary
reports only three reports were included in the study which all of them were
Randomized Clinical Trial with placebo control. Considering the efficacy extracted
from the reports, the ICER for each treatment doses was calculated. In pregabalin
450 mg/day, the ICER for domestic generic medicine was 0.72 dollar per day per
pain score reduction and for imported brand (Lyrica) was 6.47 dollar per day per
pain score reduction and for pregabalin 600 m/day these results were 0.78 and 5.53
respectively. CONCLUSIONS: Our analysis indicated that pregabalin in the treat-
ment doses of 300, 450, 600 mg/day is cost- effective and could be included into
insurance positive list.
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OBJECTIVES:Conventional treatment of organophosphate (OP) poisoningwith oxi-
mes has had limited success. Fresh frozen plasma (FFP), acting as a bioscavenger to
clean up free OP has been recently proposed as a treatment. In this study, we
undertook a meta-analysis to evaluate the efficacy of FFP in management of OP
poisoning to explore if this bioscavenger therapy can be effective and cost saving in
health system or not.METHODS: All relevant databases were searched (till Febru-
ary 2012) for all clinical effects of FFP in OP poisoning. The inclusion criteria were
death, development of intermediate syndrome, need for ventilation, and adverse
effects. Cost data were collected from standard cost list. Cost-effectiveness grid of
adding on FFP was calculated per consequence and compared with the conven-
tional regimen. RESULTS:A total of 3 studies and 157 patients were included in the
meta-analysis. Overall, we did not find significant effectiveness for FFP to prevent
death (RR 1.01, 95% CI 0.32-3.4) or intermediate syndrome (RR 0.67, 95% CI 0.04-
12.39). Since FFP in Iran is provided free of charge, the 
 cost is zero. Considering
direct cost and clinically important differences between effectiveness of FFP sup-
plementing and conventional therapy (
 effectiveness (for avoiding intermediate
syndrome)  7), however economics evaluations is not necessary according to
cost-effectiveness grid but it could be considered dominate. CONCLUSIONS: Re-
sults do not support significant efficacy of FFP in reduction of death or intermediate
syndrome in patientswith OP poisoning. FFP use, however, has no impact in health
cost; by consideration of only direct costs; the possibility of its benefit in lowering
rate of intermediate syndrome in terms of productivity loss and indirect cost
should be considered in future studies.
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OBJECTIVES: Bone Marrow transplantation is the only therapeutic option that can
cure thalassemia disease. Reduced intensity hematopoietic stem cell transplanta-
tion (RI-HSCT) has demonstrated a high cure rate with minimal complications
compared to other options. Because RI-HSCT is very costly, economic justification
for its value is needed. This study aimed to estimate the cost-utility of RI-HSCT
compared with blood transfusions combined with iron chelating therapy (BT-ICT)
for adolescent and young adult with severe thalassemia in Thailand.METHODS: A
Markov model was used to estimate the relevant costs and health outcomes over
the patients’ lifetimes using a societal perspective. All future costs and outcomes
were discounted at a rate of 3% per annum. The efficacy of RI-HSCT was based a
clinical trial including a total of 18 thalassemia patients. Utility valueswere derived
directly from all patients using EQ-5D and SF-6D. Primary outcomes of interest
were lifetime costs, quality adjusted life-years (QALYs) gained, and the incremen-
tal cost-effectiveness ratio (ICER) in Thai baht (THB) per QALY gained. One-way and
probabilistic sensitivity analyses (PSA) were conducted to investigate the effect of
parameter uncertainty. RESULTS: In base case analysis, the RI-HSCT group had a
better clinical outcomes and higher lifetime costs. The incremental cost per QALY
gained was 99,548 baht. The acceptability curve showed that the probability of
RI-HSCT being cost-effective was 64% at the willingness to pay of 1 time of Thai
Gross domestic product per capita (GDP per capita), approximately US$4210 per
QALY gained. Themost sensitive parameter is discounting rate. CONCLUSIONS:At
a societal willingness to pay of 1 GDP per capita, RI-HSCT was a cost-effective and
affordable treatment for adolescent and young adult with severe thalassemia in
Thailand compared to BT-ICT.
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OBJECTIVES: To assess the incremental cost-effectiveness ratios of Immune Tol-
erance Induction (ITI) therapy with plasma derived FVIII concentrates versus on-
demand treatmentwith Recombinant FVIIa (rFVIIa) in hemophilia Awith high titer
inhibitors from Ministry of Health perspective of Iran. METHODS: This study was
based on the study of Knight et al, which evaluated the cost-effectiveness ratios of
different treatment for hemophilia A with high-responding inhibitors. To adapt
Knight’ Results to the Iranian context, a few clinical parameters were varied and
cost data were replaced with the corresponding Iranian estimates of resource use.
The time horizon of the analysis was 10 years. One-way sensitivity analyses were
performed varying the cost of the clotting factor, the drug dose, and the adminis-
tration frequency to test the robustness of the analysis. RESULTS: Comparison of
the incremental cost-effectiveness ratios (ICERs) between the three ITI protocols
and the On-Demand regimen with rFVIIa show that all three ITI protocols domi-
nates On-Demand regimen with rFVIIa between ITI protocols the Low-Dose ITI
protocol dominates both the Bonn ITI protocol and the Malmö ITI protocol, would
also be preferred ITI protocol. All of three ITI protocols dominate the On-Demand
strategy as they have both a lower average lifetime cost and higher QALYs gained.
The cost per QALY gained for the Bonn ITI protocol compared with the Malmö ITI
protocol was $249,391.84. The cost per QALY gained for the Bonn ITI protocol com-
pared with the Low-Dose ITI protocol was $842,307.69. CONCLUSIONS: The results
of data derived fromour study suggest that The Low-Dose ITI protocolmay be a less
expensive and/or cost-effective option compared with on-demand first-line treat-
ment with rFVIIa.
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OBJECTIVES: Treatment for haemophilia inhibitor patients has improved substan-
tially since the 1980’s and 1990’s. But from a health economic perspective, an
unmet need persists for better treatment options in terms of health-related quality
of life (HRQoL) and cost savings. Haemostatic products alone account for the big-
gest expense in the care of haemophilia patients. Congenital haemophilia with
inhibitors involves lifelong treatment, and with it, substantial long-term costs and
lowered HRQoL. METHODS: A systematic review on cost and HRQoL findings for
haemophilia treatments in economic terms was conducted on more than 280 sci-
entific studies. Fifty-five articles were retained for the execution of the project
analysis. RESULTS: The analysis shows that to counteract costs to payers (society)
and to improve patient outcomes, improved treatments could increase HRQoL.
This could be achieved with FVIII and FIX bypassing agents that have: greater
convenience through subcutaneous administration (less-painful injections, avoid-
ance of infusions), faster onset through a fast-acting rFVIIa analogue (faster reso-
lution of bleeding episodes leading to faster pain relief, sustained control, less
dosing), and longer duration through a long-acting rFVIIa derivative (fewer injec-
tions and rebleeds, arthropathy prevention). CONCLUSIONS: Improved FVIII/IX
bypassing agents for treatment of haemophilia patients with inhibitors would be a
cost-effective option for society, improving HRQoL associated with the clinical
condition.
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OBJECTIVES: There are large gaps in hemophilia treatment standards around the
world. Among developing nations, disparities in care exist resulting in sub-optimal
outcomes for patients in some countries. The objective of this analysis was to
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